Table 2. Results of single trial and direct comparison meta-analysis.
| Treatment | Study | OS | PFS | SAEs | Heterogeneity I2 (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (E/C) | HR (95% CI) | N (E/C) | HR (95% CI) | N (E/C) | OR (95% CI) | OS | PFS | SAEs | |||||
| Ate + CT vs. CT | (17-19) | 1,086/854 | 0.86 (0.75–0.97) | 1,086/854 | 0.65 (0.58–0.72) | 1,098/840 | 1.77 (1.41–2.22) | 0 | 0 | 0 | |||
| Ipi + CT vs. CT | (21-22) | 409/376 | 0.74 (0.41–1.33) | 409/376 | 0.85 (0.74–0.99) | 388/361 | 2.01 (1.50–2.70)a | 61 | 35 | – | |||
| Pem + CT vs. CT | (8-11) | 748/550 | 0.56 (0.46–0.97) | 748/550 | 0.54 (0.46–0.62) | 742/544 | 1.13 (0.89–1.43) | 0 | 0 | 0 | |||
| Niv vs. CT | (12-14) | 271/270 | 1.07 (0.86–1.33)b | 342/349 | 1.13 (0.94–1.36) | 658/833 | 0.30 (0.15–0.57) | – | 0 | 85 | |||
| Pem vs. CT | (5-7) | 791/788 | 0.74 (0.59–0.94) | 791/788 | 0.74 (0.35–1.56) | 790/765 | 0.33 (0.26–0.41) | 52 | 95 | 0 | |||
| Ate + Bev + CT vs. Bev + CT | (15,16) | 359/337 | 0.78 (0.64–0.96) | 359/337 | 0.59 (0.50–0.70) | 393/394 | 1.43 (1.08–1.89) | – | – | – | |||
| Ate + CT vs. Bev + CT | (15,16) | 349/337 | 0.88 (0.72–1.08) | – | – | 400/394 | 0.76 (0.58–1.01) | – | – | – | |||
| Ate + Bev + CT vs. Ate + CT | (15,16) | 359/349 | 0.90 (0.74–1.11) | – | – | 393/394 | 1.82 (1.37–2.42) | – | – | – | |||
| Dur + Tre vs. CT | (20) | 163/162 | 0.85 (0.61–1.17) | 163/162 | 1.05 (0.72–1.53) | 163/162 | 0.55 (0.34–0.90) | – | – | – | |||
| Dur vs. CT | (20) | 163/162 | 0.76 (0.56–1.02) | – | – | 163/162 | 0.34 (0.20–0.58) | – | – | – | |||
| Dur vs. Dur + Tre | (20) | – | – | – | – | 163/163 | 0.61 (0.34–1.08) | – | – | – | |||
| Niv + Ipi vs. Niv | (13,14) | – | – | 101/102 | 0.75 (0.53–1.07) | 576/391 | 1.99 (1.47–2.70) | – | – | – | |||
| Niv + Ipi vs. CT | (13,14) | – | – | 583/583 | 0.83 (0.72–0.96) | 576/570 | 0.81 (0.64–1.04) | – | – | – | |||
| Niv + CT vs. CT | (13,14) | – | – | 117/186 | 0.74 (0.58–0.94) | 172/183 | 1.83 (1.12–3.00) | – | – | – | |||
a, result of reference (22); b, result of reference (12). OS, overall survival; PFS, progression-free survival; SAEs, serious adverse events; E/C, experimental/control; HR, hazard ratio; OR, odds ratio; CI, confidence interval; Ate, atezolizumab; Ipi, ipilimumab; Pem, pembrolizumab; Niv, nivolumab; Bev, bevacizumab; Dur, durvalumab; Tre, tremelimumab; CT, chemotherapy.